Trials under way

223 registered trials of 56 compounds that are still running or finished without published results, from ClinicalTrials.gov, checked October 7, 2026.

Phase 3 84

SemaglutideNCT04822181: ESSENCE part 2: whether weekly 2.4 mg keeps adults with MASH alive and free of cirrhosis (severe liver scarring) over 240 weeksActive, not recruiting; completion expected April 2029
SemaglutideNCT03811561: FOCUS: long-term effect of weekly injections on diabetic eye disease (retinopathy) in type 2 diabetes, over 5 yearsActive, not recruiting; completion expected November 2027
SemaglutideNCT05726227: STEP Young: weekly injections vs placebo for obesity or overweight in children and teens aged 6–17Active, not recruiting; primary data collected October 2025, completion expected December 2026, no results yet
SemaglutideNCT07218354: CRAVE: weekly injections vs placebo for 24 weeks in 622 US veterans with alcohol use disorderRecruiting since July 2026; primary completion expected March 2029
SemaglutideNCT07770841: OASIS 5: two lower once-daily tablet doses vs placebo for weight loss over 60 weeksRecruiting since August 2026; completion expected April 2028
TirzepatideNCT05556512: SURMOUNT-MMO: whether weekly tirzepatide lowers death, heart attack, stroke, heart-artery procedures and heart failure events in 15,374 adults with obesity, over up to 5 yearsActive, not recruiting; completion expected October 2027
TirzepatideNCT06075667: SURMOUNT-ADOLESCENTS: weekly injections vs placebo for 72 weeks in 160 teens with obesity, or overweight with a weight-related conditionActive, not recruiting; main data collected June 2026, completion expected July 2029, no results yet
TirzepatideNCT06914895: SURPASS-T1D-1: tirzepatide vs placebo for blood sugar control over 40 weeks in about 905 adults with type 1 diabetes and obesity or overweightActive, not recruiting; completion expected December 2026
TirzepatideNCT07165028: SYNERGY-Outcomes: tirzepatide or retatrutide vs placebo for serious liver events in about 4,500 adults with fatty liver disease at high risk, over about 224 weeksRecruiting since October 2025; completion expected August 2032
RetatrutideNCT06383390: TRIUMPH-Outcomes: retatrutide vs placebo for heart and kidney events in about 10,000 adults with excess weight and heart artery or kidney disease, over about 248 weeksActive, not recruiting; completion expected February 2029
RetatrutideNCT06662383: TRIUMPH-5: retatrutide vs tirzepatide for weight loss over 80 weeks in about 800 adults with obesityActive, not recruiting; completion expected December 2026
RetatrutideNCT05882045: TRIUMPH-3: two doses vs placebo for 80 weeks in 1,946 adults with severe obesity and heart diseaseCompleted May 2026; no results posted or published
RetatrutideNCT05931367: TRIUMPH-4: two doses vs placebo for 68 weeks in 445 adults with obesity and knee osteoarthritis: knee pain and weightCompleted November 2025; no results posted or published
RetatrutideNCT06260722: TRANSCEND-T2D-2: retatrutide vs semaglutide for blood sugar control over 80 weeks in about 1,250 adults with type 2 diabetes on metforminActive, not recruiting; main data collected August 2026, completion expected February 2027
CagrilintideNCT07220642: RENEW 1: cagrilintide alone vs placebo for 64 weeks in about 300 adults with overweight or obesity: weight changeActive, not recruiting; completion expected June 2027
CagrilintideNCT07220759: RENEW 2: cagrilintide alone vs placebo in about 330 adults with overweight or obesity and type 2 diabetes: weight changeActive, not recruiting; completion expected June 2027
CagrilintideNCT05669755: REDEFINE 3: whether CagriSema lowers heart attack, stroke and heart death in about 7,100 adults with heart or blood vessel diseaseActive, not recruiting; completion expected October 2027
CagrilintideNCT06131437: REDEFINE 4: CagriSema vs tirzepatide 15 mg for 84 weeks in 809 adults with obesity: weight changeCompleted January 2026; no results posted or published
CagrilintideNCT07253285: Cagrilintide alone, CagriSema, semaglutide or placebo for 68 weeks in about 460 children and teens aged 8–18 with overweight or obesity: BMI changeRecruiting since January 2026; completion expected September 2033
L-CarnitineNCT05602194: Levocarnitine by mouth or IV vs standard care to prevent liver damage from asparaginase chemotherapy in 440 teens and young adults with leukemiaActive, not recruiting; primary completion expected September 2026, completion December 2028
LiraglutideNCT06361238: Liraglutide vs placebo around heart surgery in 260 adults 60 and older with type 2 diabetes, to prevent delirium (sudden confusion) after surgeryRecruiting since November 2024; completion expected March 2028
ExenatideNCT04520490: BASIC2: weekly exenatide vs placebo for 24 weeks, with family-based behavior treatment, in 63 children aged 10–12 with obesity: change in BMIActive, not recruiting; main data collected August 2025, no results yet
SurvodutideNCT06077864: SYNCHRONIZE-CVOT: 3.6 or 6.0 mg vs placebo in 5,531 adults with excess weight and heart or kidney disease or risk factors: heart attacks, strokes, heart failure and heart deathsCompleted June 2026; no results posted or published
SurvodutideNCT06632444: LIVERAGE: survodutide vs placebo in about 1,800 adults with MASH and moderate to advanced liver scarring: liver healing at 52 weeks, then cirrhosis and liver events over up to 7 yearsRecruiting; completion expected December 2031
SurvodutideNCT06632457: LIVERAGE-Cirrhosis: survodutide vs placebo in about 1,590 adults with compensated MASH cirrhosis: liver failure, transplant or death over up to 4.5 yearsRecruiting; completion expected June 2029
SurvodutideNCT06214741: 3.6 or 4.8 mg vs placebo for 52 weeks in 307 Chinese adults with overweight or obesity: weight lossCompleted January 2026; no results posted or published
MazdutideNCT06884293: Mazdutide vs semaglutide for 48 weeks in 479 Chinese adults with overweight or obesity and fatty liver disease: weight and liver fatActive, not recruiting; completion expected June 2027
MazdutideNCT06184568: DREAMS-3: mazdutide vs semaglutide in 349 Chinese adults with early type 2 diabetes and obesity: blood sugar and 10% weight loss at 32 weeksCompleted February 2026; presented as a conference abstract only, no full paper or posted results
MazdutideNCT07255209: GLORY-YOUNG: two doses vs placebo in about 180 Chinese teens aged 12–18 with obesity or overweight: BMI change at 32 weeksRecruiting; completion expected October 2028
MazdutideNCT06931028: Mazdutide vs placebo for 48 weeks in about 260 Chinese adults with moderate to severe obstructive sleep apnea and a BMI of 28 or moreRecruiting; completion expected June 2027
OrforglipronNCT07241390: Heart outcomes: orforglipron vs placebo in about 7,140 adults 50 and older with heart or blood vessel disease or chronic kidney disease, followed for about 5 yearsRecruiting since December 2025; completion expected August 2031
OrforglipronNCT06649045: ATTAIN-OSA: orforglipron vs placebo for 52 weeks in 712 adults with obstructive sleep apnea and obesity or overweightCompleted July 2026; no results posted or published
OrforglipronNCT06672939: Orforglipron vs placebo for 72 weeks in about 150 teens aged 12–17 with obesity, or overweight with a related condition: change in BMIRecruiting since November 2024; main results expected December 2027
OrforglipronNCT07153471: ATTAIN-OA PAIN: orforglipron vs placebo for 72 weeks in about 800 adults with obesity or overweight and knee osteoarthritis: knee painActive, not recruiting; completion expected May 2028
OrforglipronNCT06948422: ATTAIN-HYPERTENSION: orforglipron vs placebo in about 974 adults with high blood pressure and obesity or overweightActive, not recruiting; completion expected September 2027
DulaglutideNCT06739122: AWARD-PEDS PLUS: higher dulaglutide doses in about 55 children and teens aged 10–17 with type 2 diabetes, checking safety over 26 weeksRecruiting since January 2025; completion expected December 2027
EcnoglutideNCT07387094: Ecnoglutide vs placebo for 48 weeks in 140 Chinese adults with obesity and obstructive sleep apnea who don’t use a breathing machineRecruiting since February 2026; completion expected December 2027
EcnoglutideNCT07734311: Ecnoglutide vs placebo for 68 weeks in 360 Chinese adults with obesity and knee osteoarthritis: knee pain and weightRecruiting since August 2026; completion expected June 2028
EcnoglutideNCT07836270: SLIMMER-YOUNG: three ecnoglutide doses vs placebo in 192 Chinese teens aged 12–17 with overweight or obesity: BMI change at 40 weeksNot yet recruiting; start expected October 2026, completion September 2028
SetmelanotideNCT06760546: Setmelanotide vs placebo in about 39 people aged 4 and older with congenital (present from birth) hypothalamic obesity, a sub-study of TRANSCEND: change in BMIRecruiting since September 2025; main results expected March 2027
SetmelanotideNCT05093634: EMANATE: setmelanotide vs placebo for 52 weeks in 296 people with single-copy variants in POMC, PCSK1, LEPR, SRC1 or SH2B1Completed June 2026; the developer reported in March 2026 that all four groups missed their main goal; not published
SetmelanotideNCT06596135: Open-label extension for 28 people continuing setmelanotide after earlier trials: long-term safetyCompleted June 2026; no results posted
EnlicitideNCT06008756: CORALreef Outcomes: enlicitide vs placebo in about 14,550 adults at high heart risk: time to heart death, heart attack, stroke and other major heart eventsActive, not recruiting; primary completion expected November 2029
EnlicitideNCT06492291: CORALreef Extension: open-label enlicitide for about 3,000 adults who finished the Lipids, HeFH or AddOn trials: long-term safetyActive, not recruiting; completion expected October 2028
EnlicitideNCT07216482: Enlicitide plus rosuvastatin vs placebo in 996 adults with high cholesterol: change in LDL at 8 weeksActive, not recruiting; main data collected August 2026, completion expected November 2026
DasiglucagonNCT06588504: Dasiglucagon vs glucagon for insulin-induced lows in 38 Asian adults with type 1 diabetes, plus Japanese teens (Novo Nordisk)Completed July 2025; no results posted
DasiglucagonNCT03941236: Long-term safety extension of pump-infused dasiglucagon in 42 children with congenital hyperinsulinismCompleted May 2026; no results posted
DasiglucagonNCT05378672: Single rescue dose in 8 children under 6 with type 1 diabetes, the basis of the June 2026 label changeCompleted December 2024; results posted on the registry, no journal paper found
SS-31NCT06373731: ReNEW: 40 mg daily vs placebo for 96 weeks in 313 adults 55 and older with dry age-related macular degeneration: rate of photoreceptor lossActive, not recruiting; primary completion expected August 2027
SS-31NCT05162768: NuPower: 60 mg daily vs placebo for 48 weeks in 102 adults with mitochondrial myopathy caused by nuclear DNA mutations: 6-minute walkCompleted December 2024; no results posted or published
Thymosin Beta-4NCT05555589: SEER-2: 0.1% RGN-259 eye drops 5 times daily for 28 days vs placebo in about 70 adults with neurotrophic keratopathy (non-healing corneal sores)Registry still lists it as recruiting (last updated December 2025), with completion estimated May 2026; no results posted
AbaloparatideNCT06898060: A Chinese abaloparatide injection (QLG2128) vs teriparatide in 282 postmenopausal women with osteoporosis: spine density at 52 weeksNot yet recruiting (record last updated March 2025); completion expected May 2027
CalcitoninNCT07655804: Daily salmon calcitonin injections vs saline for 3 weeks in 168 adults with shingles: whether it prevents lasting nerve pain at 3 monthsRecruiting since July 2026; completion expected October 2027
TeduglutideNCT06973304: Open-label 24-week study of daily teduglutide in 13 Chinese adults with short bowel syndrome: share cutting IV support by at least 20%Active, not recruiting; completion expected July 2027
MK-677NCT06948214: OraGrowtH: daily oral LUM-201 vs placebo for 12 months in 150 untreated children aged 3–11 with GH deficiency: yearly growth rateRecruiting since May 2026; primary completion expected December 2027
MK-677NCT07129759: Extension offering up to 36 more months of LUM-201 to children who finish the phase 3 trial: long-term safetyNot yet recruiting; planned start February 2027, completion expected February 2030
Somatropin (HGH)NCT04867317: Somatropin vs placebo for 6 months in 172 US veterans with mild traumatic brain injury and adult GH deficiency: quality of lifeRecruiting since January 2025; completion expected September 2029
MacimorelinNCT04786873: Macimorelin test vs arginine and clonidine tests in 101 children and teens with suspected GH deficiency: diagnostic accuracyCompleted June 2024; no results posted, but the July 2026 US label says accuracy wasn’t demonstrated
OctreotideNCT05050942: SORENTO: monthly self-injected octreotide depot (CAM2029) vs octreotide LAR or lanreotide in 332 people with gut and pancreatic neuroendocrine tumors: time before tumors growActive, not recruiting; primary completion expected November 2026
OctreotideNCT07623824: A new long-acting octreotide injection (SYHX2008) vs Sandostatin LAR in 154 people with active acromegaly: IGF-1 control at week 28Not yet recruiting; completion expected December 2029
OctreotideNCT07479784: One 30 mg octreotide depot injection a week before surgery vs placebo in 230 people having distal pancreas removal: pancreatic fistula within 60 daysNot yet recruiting; completion expected December 2028
Melanotan 1NCT06109649: CUV105: implants plus narrowband UV light vs light alone in about 200 people aged 12 and older with vitiligoActive, not recruiting; completion was expected June 2026 (record last updated July 2025); no results posted
hCGNCT07108621: 8 weeks of low-dose hCG “priming” vs placebo before IVF in 80 women with low ovarian reserve: eggs retrievedRecruiting since January 2026; primary completion expected March 2028
OxytocinNCT04949633: IV oxytocin with early breaking of the waters vs a second round of cervical ripening in 1,494 women whose cervix stayed unready after 24 hours: cesarean rateRecruiting since September 2021; completion expected November 2027
TriptorelinNCT06129539: LIBELULA: a new 12-month triptorelin depot (Debio 4326) in 56 children aged 5–8 with central precocious puberty, single-armActive, not recruiting; primary completion expected October 2026, completion February 2028
TriptorelinNCT05328258: ProFertil: triptorelin vs placebo injections during chemotherapy to protect fertility in 500 women and teens aged 14–42 with cancerRecruiting since March 2023; primary completion expected January 2028
TriptorelinNCT06150703: IVF: a triptorelin trigger shot plus nasal nafarelin vs the standard hCG trigger plus progesterone in 652 women: live birthsRecruiting since June 2024; completion expected September 2027
DesmopressinNCT06020495: DASSOH: routine IV desmopressin vs standard care to keep sodium from rising too fast in 260 adults with severe hyponatremiaRecruiting since December 2024; completion expected November 2026
DesmopressinNCT05467033: STOP-BLEED: IV desmopressin vs saline before kidney biopsy in 424 adults: bleeding within 24 and 48 hoursListed as recruiting; completion was expected August 2026
DesmopressinNCT06337838: BRACKETS pilot: desmopressin, tranexamic acid or placebo in 100 adults with kidney disease having surgeryRecruiting since June 2025; completion expected June 2027
DesmopressinNCT07012837: REDES-BLEED: prolonged desmopressin infusion vs placebo in 112 adults at high bleeding risk in heart surgeryNot yet recruiting; completion expected August 2027
PalopegteriparatideNCT07081997: Doses above 30 mcg a day in 36 adults already needing 30 mcg or more, over 78 weeksRecruiting since May 2026; completion expected June 2028
PalopegteriparatideNCT07706764: Single-arm trial in 12 teens aged 12–17 with chronic hypoparathyroidism, in Europe, over 234 weeks: safety and calcium controlRecruiting since April 2026; primary completion expected August 2027
PalopegteriparatideNCT05387070: PaTHway China: palopegteriparatide vs placebo for 26 weeks, then open-label, in 81 Chinese adultsCompleted January 2026; no results posted
LeuprolideNCT04906395: TOL2506, a 3-month 30 mg leuprolide depot under the skin, with hormone therapy to suppress the ovaries in 250 premenopausal women (and some men) with HR-positive breast cancerActive, not recruiting; completion expected November 2026
LeuprolideNCT06449027: A 42 mg leuprolide emulsion every 24 weeks vs 11.25 mg microspheres every 12 weeks, both with tamoxifen, in 211 premenopausal women with breast cancer: estrogen suppressionActive, not recruiting; completion was expected March 2026, no results posted
LeuprolideNCT06650579: REVELUTION-2: leuprolide vs relugolix, each with abiraterone, in 72 men with advanced prostate cancer: blood pressure and heart effectsRecruiting since January 2025; completion expected July 2029
GanirelixNCT05994378: Oral SHR7280 tablets vs ganirelix injections in 317 women having IVF or ICSI: eggs retrieved and LH surge preventionCompleted May 2025; no results posted
CerebrolysinNCT06052787: Two 10-day courses, alone or with amantadine, vs usual care in 150 ICU patients with traumatic brain injury: consciousness and disability scoresCompleted August 2025; no results posted or published
Thymosin Alpha-1NCT05086614: Thymosin alpha-1 vs observation after surgery for high-risk stage II–III colorectal cancer in 2,500 adults: 3-year disease-free survivalRecruiting since April 2021; completion expected March 2027 (registry record last updated in 2021)
IcotrokinraNCT06878404: ICONIC-PsA 1: daily icotrokinra vs placebo in 552 adults with active psoriatic arthritis who haven’t had biologic drugs: joint improvement (ACR 20) at week 16Active, not recruiting; main data collected May 2026, no results reported
IcotrokinraNCT06807424: ICONIC-PsA 2: daily icotrokinra vs placebo in about 750 adults with active psoriatic arthritis, including people already treated with biologics: ACR 20 at week 16Recruiting; primary completion expected February 2027
IcotrokinraNCT07196748: ICONIC-UC: induction and maintenance vs placebo in about 882 adults with moderate-to-severe ulcerative colitis (plus an open-label teen study): remission at weeks 12 and 40Recruiting; primary completion expected January 2028
IcotrokinraNCT06934226: ICONIC-ASCEND: icotrokinra vs placebo and ustekinumab, an injected IL-12/23 antibody, in 752 people with moderate-to-severe plaque psoriasisActive, not recruiting; main data collected November 2025, no journal paper yet

Phase 2/3 7

DulaglutideNCT07282041: RADIANT: dulaglutide for 1 year in 130 adults with severe narrowing of brain arteries, measuring how well the brain’s blood vessels can widenRecruiting since December 2025; completion expected December 2030
PramlintideNCT06046417: A fully automated insulin (Lyumjev) and pramlintide delivery system vs a hybrid closed loop with carbohydrate counting in 30 adults with type 1 diabetesStatus unknown (last updated April 2024); completion was expected June 2025, no results posted
EnlicitideNCT07058077: Enlicitide vs placebo in about 153 children and teens with HeFH: drug levels, LDL change and safetyRecruiting since August 2025; completion expected 2037
OctreotideNCT05281328: POSITANO: octreotide subcutaneous depot (CAM2029) vs placebo in 71 people with symptomatic polycystic liver disease: change in liver volume over a yearActive, not recruiting; results posted June 2026, not yet published in a journal
OxytocinNCT04903002: Two-week courses of nasal oxytocin at two doses vs placebo, in a crossover design, in 336 adults with chronic pain: pain and functionActive, not recruiting; completion was expected March 2026, no results posted
GonadorelinNCT04390646: Pulsed gonadorelin by pump vs a placebo pump for 24 weeks in 56 people aged 16–50 with Down syndrome: cognitionRecruiting since August 2020; completion expected December 2028
Thymosin Alpha-1NCT07675980: Thymosin alpha-1 vs placebo in 136 women with repeated embryo implantation failure during IVF: live birthsRecruiting since February 2026; completion expected June 2027

Phase 2 46

TirzepatideNCT05536804: TREASURE-CKD: tirzepatide vs placebo for 52 weeks in 134 adults with obesity and chronic kidney disease, measuring kidney fat and oxygen on MRICompleted July 2026; no results posted or published
L-CarnitineNCT06564909: A 5 g IV dose, then oral carnitine, added to standard care in 76 people having angioplasty for a heart attack: markers of heart injuryActive, not recruiting; completion expected December 2026
ExenatideNCT05610800: Weekly exenatide vs placebo, added to nicotine patches and counseling, in 140 adults trying to quit smoking: quit rates and weight gain after quittingCompleted March 2026; no results posted or published
ExenatideNCT05356104: GAPP-SVD: weekly exenatide or semaglutide vs usual care for 78 weeks in 110 people with small vessel disease of the brain, measured on MRIRecruiting since May 2022; completion expected December 2027
MazdutideNCT06817356: Mazdutide vs placebo for 28 weeks in 308 adults with alcohol use disorder: drinking days and amountsCompleted May 2026; no results posted or published
EcnoglutideNCT07073417: SLIMMER-UP-SWITCH: ecnoglutide vs semaglutide injections, with treatment switching, in 163 Chinese adults with obesity: weight change at 48 weeksActive, not recruiting; completion expected August 2027
EcnoglutideNCT07281937: Weekly oral ecnoglutide tablets (VRB-101) vs placebo for 21 weeks in 206 US adults with obesity, or overweight with a related conditionCompleted July 2026; no results posted or published
SetmelanotideNCT06772597: Open-label setmelanotide for up to 52 weeks in 18 people aged 6–65 with Prader-Willi syndrome, a genetic cause of constant hunger: safety, weight and hungerActive, not recruiting; primary completion expected October 2026
EnlicitideNCT07614984: MK-7262, an experimental lipoprotein(a)-lowering drug, alone and with enlicitide in about 750 adults with high lipoprotein(a)Recruiting since June 2026; completion expected October 2027
NAD+NCT07839130: PEDI-NAD: IV NAD+ for 7 days vs placebo in 180 Chinese children with weak heart pumping: change in ejection fractionNot yet recruiting; completion expected December 2028
SS-31NCT07275424: SHAPE: open-label pilot of daily injections for 4 weeks in 30 adults aged 65–80: safety and tolerabilityRecruiting since November 2025; completion was estimated for April 2026, but the record hasn’t been updated since December 2025
GlutathioneNCT05266417: Nasal insulin plus glutathione twice daily vs placebo for 24 weeks in 56 people with Parkinson’s disease: verbal fluencyRecruiting; completion expected November 2027
GlutathioneNCT07263841: Glutathione vs tranexamic acid injected into facial skin (mesotherapy) in 60 people with dark patches after burnsActive, not recruiting; completion was expected March 2026; no results posted
Thymosin Beta-4NCT07586865: Recombinant thymosin beta-4 (NL005) by IV once daily for 7 days vs placebo in 189 adults after a major heart attack (STEMI) treated by artery opening: heart scar size at 90 daysNot yet recruiting as of its last update (May 2026); completion expected May 2028
LarazotideNCT05747534: Larazotide vs placebo capsules four times daily for 21 days in 107 people aged 7–50 with long COVID: side effects and time to symptom resolutionCompleted June 2026; no results posted
AbaloparatideNCT03841058: Abaloparatide vs placebo in 96 postmenopausal women (plus abaloparatide in men) having spinal fusion surgery: bone bridging across the fusionActive, not recruiting; completion expected February 2027
AbaloparatideNCT07587775: Abaloparatide in 60 adults with osteoporosis: change in the vertebral bone quality scoreEnrolling by invitation since June 2026; completion expected December 2028
TeduglutideNCT07537686: GAME: a 30-day course in 55 undernourished women with environmental enteric dysfunction (gut damage from repeated infections): gut-lining biopsy scoresNot yet recruiting; completion expected December 2027
LinaclotideNCT03796884: Linaclotide vs placebo for 7 days before colonoscopy or surgery in 150 people with colorectal adenomas or stage 0–3 colorectal cancer: whether it switches on its target (cGMP) in the tissueActive, not recruiting; completion was estimated for September 2026, no results posted
PlecanatideNCT07723924: Two weight-based plecanatide doses vs placebo for 8 weeks in 180 children and teens aged 6–17 with functional constipation: weekly bowel movementsRecruiting since August 2026; completion expected October 2027
TesamorelinNCT06554717: TRIUMPH: daily Egrifta WR vs placebo, both with home exercise, for 24 weeks in 100 adults aged 50–80 with HIV: chair-stand speed and muscle healthRecruiting since July 2025; completion expected December 2028
TesamorelinNCT03150511: Tesamorelin vs no treatment after surgical repair of arm or hand nerve injuries, in about 36 adults: pinch strength and nerve recovery over 12 monthsRecruiting since June 2018; completion expected December 2027
TesamorelinNCT03375788: Tesamorelin 2 mg daily vs placebo for 12 months in 51 adults with obesity and fatty liver, not limited to HIV: change in liver fatCompleted January 2025; summary results posted on the registry, no journal paper yet
MK-677NCT07754045: LUM-201 or placebo added to oral semaglutide for 26 weeks in 202 adults aged 60–84 with obesity and mild physical impairment: physical functionNot yet recruiting; planned start February 2027, completion expected February 2028
MK-677NCT05796440: Extension following 60 children with GH deficiency from earlier LUM-201 trials for up to 36 months: long-term safetyEnrolling by invitation since August 2023; completion expected April 2028
MK-677NCT04806854: OraGrowtH212: GH release pattern and drug levels over 6 months on two LUM-201 doses in 24 children with GH deficiencyActive, not recruiting; completion expected July 2030
Somatropin (HGH)NCT04375657: TRIIM-X: GH with DHEA and metformin vs DHEA and metformin in 85 adults aged 40–80: thymus regrowth and epigenetic ageListed as recruiting; completion was expected December 2025, record not updated since May 2025
MecaserminNCT03253263: Mecasermin rinfabate (OHB-607, IGF-1 bound to its binding protein) vs standard care in 295 extremely premature infants: prevention of bronchopulmonary dysplasia, a chronic lung diseaseActive, not recruiting; main data collected July 2026, completion expected January 2028
hCGNCT07481370: hCG 2,000 units 3 times a week vs isotretinoin pills for 3 months in 100 men with low or absent sperm: motile sperm in semenEnrolling by invitation since April 2026; completion expected December 2027
Kisspeptin-10NCT05896293: Two weeks of pulsed kisspeptin-10 by under-the-skin pump in 36 adults with hypogonadotropic hypogonadism (low sex hormones from a brain cause): LH pulsesRecruiting since February 2023; completion expected May 2028
Kisspeptin-10NCT07224438: Two weeks of pulsed kisspeptin-10 by under-the-skin pump in 20 women with hypothalamic amenorrhea (periods stopped by stress, weight loss or exercise): LH pulsesRecruiting since December 2025; completion expected May 2030
PT-141NCT06565611: Bremelanotide with tirzepatide vs either alone or placebo for 8 weeks in about 108 adults with obesity: weight changeActive, not recruiting; primary data collected February 2025; no results posted or published
PT-141NCT05709444: Open-label twice-daily 0.5 mg injections added to standard care for 6 months in 16 adults with diabetic kidney disease: urine proteinCompleted April 2024; no results posted or published
OxytocinNCT06194851: Nasal oxytocin vs placebo before each session of brief couples therapy in 240 veterans with PTSD: PTSD severityRecruiting since October 2024; completion expected September 2028
OxytocinNCT04551482: Nasal oxytocin vs placebo for 12 weeks in 55 youths aged 10–18 with obesity: change in BMIRecruiting since July 2021; completion expected February 2027
OxytocinNCT04523922: Nasal oxytocin vs placebo added to 12 weeks of exposure therapy in 175 adults with alcohol use disorder and PTSD: drinking and PTSD symptomsCompleted April 2026; no results posted or published
TriptorelinNCT07254429: COMPASS: one triptorelin depot injection vs saline, estrogen gel or testosterone gel in 192 postmenopausal women with hot flashes: bone turnover over 8 weeksRecruiting since October 2025; completion expected May 2028
TriptorelinNCT05982093: PremiÈRe: elacestrant with or without triptorelin vs tamoxifen for about a month before surgery in 96 premenopausal women with breast cancerRecruiting since February 2023; completion expected December 2026
DesmopressinNCT06635629: Desmopressin stimulation test to tell apart causes of ACTH-dependent Cushing syndrome in 140 adults (NIH)Recruiting since December 2024; completion expected January 2029
CosyntropinNCT03514589: NeSST2: nasal tetracosactide vs IV in 12 participants, to develop a needle-free short Synacthen testListed as recruiting, but its estimated December 2025 completion has passed; no results posted
LeuprolideNCT07158021: Lower-dose and higher-dose leuprolide vs goserelin for suppressing the ovaries in 75 pre- or perimenopausal women with breast cancerRecruiting since January 2026; completion expected January 2028
LeuprolideNCT01746849: Palifermin with leuprolide (or degarelix) to speed immune recovery in 82 people after a T-cell-depleted stem cell transplantActive, not recruiting; completion expected December 2026
CerebrolysinNCT06339411: 30 mL daily for 10 days vs placebo after extended-window clot removal (thrombectomy) for stroke, in 100 adults: final stroke size on MRINot yet recruiting; planned start September 2026, completion expected December 2030
CerebrolysinNCT05755997: Cerebrolysin vs placebo in a crossover trial of 30 people with CADASIL, an inherited small-vessel brain disease: thinking tests and white matter lesionsActive, not recruiting; completion expected December 2026
Thymosin Alpha-1NCT06139419: 4.8 mg added to chemoradiotherapy and follow-on immunotherapy in 114 adults with locally advanced lung cancer: how many complete immunotherapyCompleted June 2026; no results posted or published
VIPNCT04488081: I-SPY COVID platform: inhaled aviptadil, 100 mcg three times daily for up to 14 days, in critically ill adults with COVID-19, among other drugsAviptadil arm closed; platform active, not recruiting (completion expected July 2030); no aviptadil results published

Phase 1/2 3

LinaclotideNCT06692673: Pilot: linaclotide with a sports drink, instead of polyethylene glycol, as the only bowel prep before colonoscopy in 10 hospital patientsListed as recruiting (last updated January 2026); completion was estimated for July 2026
Follistatin-344NCT07443826: A virus-delivered follistatin gene injected into limb muscles, alone or with a gene plasmid for blood-vessel growth, in 12 adults aged 35–75 with age-related muscle loss: safetyRecruiting since June 2026 at a clinic in Honduras; completion expected June 2028
Melanotan 1NCT06388642: Blood levels after the implant in 28 people with EPP aged 12–70Completed January 2025; results posted to the registry, not yet published

Phase 1 21

L-CarnitineNCT05355311: Open pilot of oral L-carnitine, 2.97 g a day for 6 weeks, in 24 young adults with alcohol use disorder and depression: alcohol cravingCompleted May 2025; no results posted or published
LiraglutideNCT07225816: How long fasting, and briefly pausing liraglutide or semaglutide, take to leave the stomach empty after a meal, a question for anesthesia safety; 71 adultsRecruiting since November 2025; completion expected January 2027
ExenatideNCT05670379: LIBERATE-1: an exenatide implant under the skin of the arm, releasing about 52 mcg a day for 9 weeks, vs weekly injections in 24 adults: drug levels and safetyCompleted August 2025; no results posted or published
SurvodutideNCT06745284: Survodutide vs semaglutide in 64 adults with obesity: calories burned during sleep, measured in a sealed room, once weight has fallen 10%Active, not recruiting; completion expected January 2027
DulaglutideNCT07313813: How fasting time and briefly withholding dulaglutide affect food left in the stomach after a meal, checked by ultrasound, in 20 adults with type 2 diabetes; a question for anesthesia safetyCompleted August 2026; no results posted or published
PramlintideNCT03560960: A single pramlintide dose as a blood test for Alzheimer’s disease: whether it briefly raises amyloid-beta levels in the blood, in 57 peopleActive, not recruiting; completion expected November 2026
GlucagonNCT07212868: Glucagon infusion and a glucagon-receptor-blocking antibody (REMD-477) to study blood sugar control in 150 adults with and without bariatric surgeryRecruiting since February 2026; completion expected June 2030
NAD+NCT06558253: IV NAD+ for 21 days at three doses in 12 adults after cord-blood transplant for blood cancers: safety and blood-count recoveryRecruiting; completion expected September 2026
NAD+NCT05849519: IV NAD+ for 7 days added to usual care vs usual care alone in 36 adults with sudden hearing lossStatus unknown; completion was planned for February 2024; no results
GlutathioneNCT06896422: Glutathione added to PD-1 antibody and platinum chemotherapy vs the same treatment alone in 80 people with advanced lung cancer: progression-free survivalRecruiting; primary completion expected December 2026
BPC-157NCT07803250: Daily injections vs a saline control for 90 days after rotator cuff (shoulder tendon) repair surgery, in a small pilot: shoulder strengthNot yet recruiting; planned start January 2027, completion expected August 2027
TeriparatideNCT05965167: New oral PTH(1–34) tablet formulations vs earlier EB613 tablets and Forteo injections in 45 adults: blood levels and safetyCompleted February 2026; no results posted
LinaclotideNCT05107219: A single dose of linaclotide or plecanatide, or no drug, before upper endoscopy in 43 adults: the cGMP signal in the duodenum, the first part of the small intestineCompleted February 2026; no results posted or published
LinaclotideNCT07569419: MRI crossover study in 26 healthy adults: where in the gut linaclotide draws in water, as groundwork for a trial in cystic fibrosisRecruiting since March 2026; completion expected October 2026
PlecanatideNCT05107219: A single dose of plecanatide or linaclotide, or no drug, before upper endoscopy in 43 adults: the cGMP signal in the duodenum, the first part of the small intestineCompleted February 2026; no results posted or published
Follistatin-344NCT07285629: Open-label plasmid carrying the follistatin and klotho genes in 14 adults aged 50–80: blood follistatin levels and side effectsCompleted April 2026 at clinics in Honduras, outside FDA oversight per its record; no results posted or published
OctreotideNCT06881888: An octreotide nasal spray 3× daily vs placebo in 60 people with diabetic macular edema: retinal thickness and vision after a monthNot yet recruiting; planned start August 2026, completion expected December 2027
Kisspeptin-10NCT05633966: Two weeks of pulsed kisspeptin-10 by under-the-skin pump in 13 women with reproductive disorders: follicle growth or ovulationCompleted August 2025; no results posted or published
Kisspeptin-10NCT07224490: A single IV dose of kisspeptin-10 as a test of the brain’s reproductive signaling in 40 adults with and without long COVID: LH responseRecruiting since March 2026; completion expected May 2030
GanirelixNCT05751252: A single low dose of ganirelix to damp LH pulses and lower androgens in 20 lean women with polycystic ovary syndromeCompleted February 2025; no results posted
Thymosin Alpha-1NCT06821100: One or two 4.8 mg doses before a COVID-19 booster in 75 adults 65 and older: safety and vaccine responseRecruiting since December 2024; completion expected December 2026

Phase 4 30

L-CarnitineNCT05673239: Non-randomized study of IV levocarnitine on dialysis days in 1,008 hemodialysis patients: heart pumping strength (ejection fraction) at 12 weeksCompleted June 2024; no results posted or published
L-CarnitineNCT07642076: Added L-carnitine vs standard care in 58 critically ill patients with liver disease: kidney function and clotting testsRecruiting; completion expected March 2027
LiraglutideNCT05390892: PRECIDENTD: a GLP-1 drug (dulaglutide, liraglutide or semaglutide) vs an SGLT2 inhibitor pill in 6,000 adults with type 2 diabetes and heart risk, counting heart, kidney and death eventsRecruiting since September 2022; completion expected March 2029
LiraglutideNCT06742710: LITOP: liraglutide 3 mg plus metformin vs metformin alone in 890 women with obesity, PCOS and infertility before frozen embryo transfer, measuring live birthsRecruiting since May 2025; completion expected December 2029
DulaglutideNCT05390892: PRECIDENTD: a GLP-1 drug (dulaglutide, liraglutide or semaglutide) vs an SGLT2 inhibitor pill in 6,000 adults with type 2 diabetes and heart risk, counting heart, kidney and death eventsRecruiting since September 2022; completion expected March 2029
DulaglutideNCT06324461: GLUMINS: one dulaglutide dose 1–14 days before non-cardiac surgery vs usual care in 372 adults, to prevent heart muscle injury after surgeryRecruiting since March 2024; completion expected December 2028
LixisenatideNCT07307235: Insulin glargine plus lixisenatide vs usual insulin care in 1,316 Chinese adults with type 2 diabetes not controlled on pills: HbA1c at 24 weeksRecruiting since December 2025; completion expected December 2027
LixisenatideNCT06671587: Soli-CGM: insulin glargine plus lixisenatide vs insulin glargine alone in 678 Chinese adults new to insulin, measured with continuous glucose monitors over 20 weeksRecruiting since December 2024; completion was expected September 2026
LixisenatideNCT07117240: Insulin glargine plus lixisenatide vs standard insulin therapy in 100 people with diabetes caused by steroid treatment, over 6 monthsEnrolling by invitation since July 2025; completion expected July 2028
LixisenatideNCT07274644: Insulin glargine plus lixisenatide vs insulin glargine on liver fat over 12 weeks in 36 adults with type 2 diabetes and fatty liver disease (MASLD)Active, not recruiting; completion was expected July 2026, no results yet
LixisenatideNCT06716424: Single-arm safety study of insulin glargine plus lixisenatide in 105 adults with type 2 diabetes in India, over 25 weeksCompleted June 2026; no results posted or published
SetmelanotideNCT07674290: Single-center study of real-world setmelanotide use in about 200 people with Bardet-Biedl syndrome and other MC4R pathway disorders: BMI, blood fats and liver fatRecruiting; completion expected December 2030
GlucagonNCT07427251: Low-dose glucagon vs glucose before exercise after a meal, in 18 adults with type 1 diabetes using automated insulin deliveryRecruiting since April 2026; primary completion expected May 2027, completion May 2028
GlucagonNCT06986603: How blood sugar responds to different glucagon doses in 28 adults with and without low blood sugar after bariatric surgeryActive, not recruiting; completion expected September 2026
GlucagonNCT07818707: Glucagon turnover and liver sugar output before and after meals in 40 adults with and without post-bariatric low blood sugarRecruiting since January 2026; completion expected January 2027
SS-31NCT07531251: 4TAZPower: daily injections vs placebo for 72 weeks in 48 males aged 5–55 with Barth syndrome, to confirm the benefit behind the accelerated approvalRecruiting since July 2026; primary completion expected September 2029
TeriparatideNCT04589819: Teriparatide STRONG: daily teriparatide vs placebo after shin-bone stress fractures in 183 US soldiers: time to full return to dutyEnrolling by invitation; completion expected December 2026
TeriparatideNCT06558188: Romosozumab with or without daily teriparatide in 50 postmenopausal women with osteoporosis: change in spine bone densityRecruiting since February 2025; completion expected April 2028
TeriparatideNCT04522622: Teriparatide for 18 months vs no treatment in 48 adults with low-turnover (adynamic) bone disease from chronic kidney diseaseRecruiting since December 2021; completion expected September 2027
AbaloparatideNCT04467983: Adding abaloparatide to ongoing denosumab vs denosumab alone in 70 postmenopausal women: hip and spine bone densityActive, not recruiting; completion expected December 2026
CalcitoninNCT03935984: Calcitonin to lower calcium before repeat parathyroid scans in 37 people with primary hyperparathyroidism: scan sensitivityRecruiting since May 2019; completion expected December 2026
LinaclotideNCT03119584: Crossover trial of linaclotide vs placebo in 23 adults with type 2 diabetes and chronic constipation: bowel movement frequencyActive, not recruiting; completion expected January 2027
Somatropin (HGH)NCT07691125: 4 weeks of somatropin in 100 adults with short bowel syndrome on IV nutrition, open-label: change in IV nutrition volumeRecruiting since July 2024; completion expected June 2028
Somatropin (HGH)NCT05681299: GH with and without liraglutide, in 3-week crossover periods, in 40 healthy and GH-deficient adults: the appetite signal AgRP and metabolismRecruiting since May 2023; completion expected April 2028
hCGNCT07523022: hCG and/or FSH injections vs clomiphene pills for 12 weeks in 500 men with low sperm counts: semen quality and IVF outcomesEnrolling by invitation since September 2024; completion expected December 2026
PT-141NCT06867835: A single 1.75 mg dose in 10 breastfeeding women: how much bremelanotide reaches breast milk over 24 hoursCompleted November 2025; no results posted or published
CetrorelixNCT07350317: Progesterone injected under the skin vs cetrorelix to suppress the LH surge in 230 women having freeze-all IVF cyclesNot yet recruiting (start planned January 2026); completion expected February 2027
GanirelixNCT05954962: Oral micronized progesterone vs ganirelix to prevent the LH surge in 150 women having ovarian stimulation: mature eggsCompleted August 2025; no results posted
GanirelixNCT06745466: Ganirelix used to switch off ovarian hormones in 30 midlife women, to study estradiol, stress, sleep and blood vessel functionRecruiting; completion expected October 2027
CerebrolysinNCT06897176: Cerebrolysin vs placebo with speech therapy in 40 people with non-fluent aphasia after stroke: language scoresRecruiting since March 2025; completion expected December 2027

Other studies 32

LiraglutideNCT01511393, Observational registry: US registry of new medullary thyroid cancer cases, looking for any rise linked to liraglutide, weekly exenatide and other GLP-1 drugsEnrolling by invitation since 2012; planned to run to December 2039
ExenatideNCT05663515, Observational safety study: EXCEED: pancreatic cancer risk in about 24,000 adults with type 2 diabetes who started exenatide vs other non-GLP-1 diabetes drugs, using records from 7 European countriesRecruiting since September 2024; completion expected October 2026
PramlintideNCT07506369, Not applicable (physiology study): Pramlintide infusion with or without pancreatic polypeptide, another pancreatic hormone, in 18 healthy adults: effect on how much they eatRecruiting since April 2026; completion expected October 2028
PramlintideNCT07340788, Not applicable (physiology study): Whether a pramlintide infusion triggers migraine attacks in 21 people with migraine without aura, compared with placeboNot yet recruiting; completion expected October 2028
PramlintideNCT07340775, Not applicable (physiology study): Whether pramlintide triggers migraine-like headache in 21 people with lasting headache after a mild brain injury, compared with placeboNot yet recruiting; completion expected December 2028
NAD+NCT07328100, Not applicable: IV NAD+ (“coenzyme I”) for 7 days vs saline in 60 adults with stiff arteries (vascular aging)Not yet recruiting as of its last update; completion expected December 2027
NAD+NCT06919328, Not applicable: 100 mg NAD+ or nicotinamide riboside by IV push, muscle or under-the-skin shot vs placebo in about 70 adults: injection pain and discomfortRegistry still shows recruiting with a June 2025 completion date; no results posted
TeriparatideNCT03770338, Not applicable: One month of teriparatide before lumbar fusion surgery vs none in 192 people with osteoporosis: screw grip strength during surgeryActive, not recruiting; main data collected March 2026, no results posted
CalcitoninNCT06330168, Not applicable: Calcitonin added to a nerve block before chest surgery (thoracotomy) in 92 patients: morphine use and chronic pain at 3 monthsCompleted May 2026; no results posted
CalcitoninNCT07033104, Not applicable: Calcitonin added to a bupivacaine nerve block for cesarean section in 70 women: time to first rescue pain reliefListed as recruiting, but its estimated September 2025 completion has passed; no results posted
TeduglutideNCT01990040, Observational: International registry of 1,806 people with short bowel syndrome: colorectal cancer and other long-term risks with or without teduglutide, over 10 yearsActive, not recruiting; completion expected June 2032
TeduglutideNCT05023382, Observational: All-case safety surveillance of 250 people treated with Revestive in Japan, followed for up to 36 monthsCompleted July 2026; no results posted
IpamorelinNCT07717866, Observational: Trifecta: veterans with PTSD and brain injury get a hormone program that includes ipamorelin, then ibogaine, 5-MeO-DMT and magnetic brain stimulation; ipamorelin’s own effect can’t be separatedActive, not recruiting; completion expected November 2026
Somatropin (HGH)NCT07568574, Not applicable: Medically supervised performance-enhancing drugs, including hGH, for up to 25 weeks in 60 elite athletes: side effects over 5.5 yearsEnrolling by invitation since March 2026; completion expected 2033
MecaserminNCT00903110, Observational: Global Increlex registry: long-term safety, including tumors, in children and teens with severe primary IGF-1 deficiencyRecruiting since December 2008; completion expected December 2027
hCGNCT07540611, Not applicable: hCG plus FSH vs standard care over 16 weeks in 860 men with no sperm in the semen and low hormone levels: usable sperm for IVFNot yet recruiting; planned start July 2026, completion expected July 2027
PalopegteriparatideNCT07264634, Observational: How much palopegteriparatide passes into breast milk, in about 10 breastfeeding women on treatmentRecruiting since March 2026; completion expected August 2027
PalopegteriparatideNCT07345494, Observational registry: Global pregnancy registry: outcomes for mothers and babies exposed during pregnancy or breastfeedingRecruiting since February 2026; completion expected January 2036
CosyntropinNCT05149638, Not applicable: Cosyntropin tests in 90 people with suspected adrenal insufficiency, to reset the cortisol cutoff for a newer, more specific assayRecruiting since February 2022; completion expected December 2027
CosyntropinNCT07866326, Observational: Morning cortisol and Synacthen tests in 120 people with rheumatoid arthritis on low-dose steroids: how common adrenal insufficiency isRecruiting since July 2026; completion expected July 2027
CosyntropinNCT03793114, Not applicable: Cosyntropin tests in 200 people with Addison’s disease: how many still make some cortisol and aldosteroneActive, not recruiting; completion expected December 2029
CetrorelixNCT06023602, Not applicable: Generic vs original cetrorelix 0.25 mg daily in 1,338 women having IVF or ICSI: cumulative live births (non-inferiority)Recruiting; completion was expected December 2025, no results posted
CetrorelixNCT07732348, Not applicable: Oral linzagolix vs injectable antagonists (ganirelix or cetrorelix) in 120 women having IVF: mature eggs retrievedNot yet recruiting; start planned September 2026, completion expected December 2026
CetrorelixNCT07836400, Observational: Half-dose (0.125 mg) vs standard 0.25 mg daily cetrorelix in 160 women with a BMI of 25 or more having ICSI: clinical pregnancyNot yet recruiting; start planned September 2026, completion expected March 2028
GanirelixNCT07732348, Not applicable: Oral linzagolix vs injectable antagonists (ganirelix or cetrorelix) in 120 women having IVF: mature eggs retrievedNot yet recruiting; start planned September 2026, completion expected December 2026
CerebrolysinNCT06677502, Not applicable: 50 mL daily for 7 days vs saline in 500 critically ill adults with delirium: delirium severityEnrolling by invitation since January 2024; completion was expected December 2025; no results posted (record last updated 2024)
ZiconotideNCT04321408, Observational: OP2C: French registry of 300 patients with refractory pain on intrathecal ziconotide: how it’s used, how well it works and its safetyRecruiting since July 2020; completion expected September 2027
ZiconotideNCT06541184, Observational: French study of 85 adults starting intrathecal ziconotide for chronic non-cancer pain: who receives it and how they fareRecruiting since October 2024; completion expected October 2029
ZiconotideNCT07499882, Observational: 24 US patients with chemotherapy-induced nerve pain on intrathecal ziconotide, followed for 2 years: pain and disability scoresNot yet recruiting (planned start May 2026); completion expected May 2028
ZiconotideNCT07733427, Not applicable: Pilot of intrathecal pump treatment, with drug mixes that can include ziconotide, for pancreatic cancer pain in 40 peopleNot yet recruiting (planned start September 2026); completion expected December 2027
Thymosin Alpha-1NCT05339529, Not applicable: PANDA II: 1.6 mg every 12 hours for 5 days vs usual care after emergency aortic dissection surgery in 600 adults: organ failure scoresCompleted July 2026; no results posted or published
IcotrokinraNCT07196722, Phase 2b/3: ICONIC-CD: icotrokinra vs placebo in about 1,092 adults with moderate-to-severe Crohn’s disease: clinical response and remission at week 12Recruiting; primary completion expected September 2028

Trials are listed by the compound tested; combination trials appear under each compound they test. Registry records that describe themselves as examples, studies run by sellers or clinics, and trials that ended more than two years ago aren’t listed. A trial’s registration isn’t a result: wait for the published paper.

By Vial Guide editorsLast reviewed October 7, 2026

How we review